共 50 条
- [1] Phase 1 Study of first-in-class dUTPase inhibitor, TAS-114 in combination with capecitabine in patients with advanced solid tumorsEUROPEAN JOURNAL OF CANCER, 2016, 69 : S119 - S119LoRusso, P.Miller, K.Shields, A.Saito, K.Yoshida, K.Aoyama, T.Winkler, R.Benedetti, F.Lenz, H. J.
- [2] Phase 1 study of first-in-class dUTPase inhibitor, TAS-114 in combination with S-1 in patients with advanced solid tumorsEUROPEAN JOURNAL OF CANCER, 2016, 69 : S117 - S118Aoyama, T.Fasolo, A.Stathis, A.Sessa, C.Hollebecque, A.Soria, J. C.Pastorino, A.Sobrero, A. S. AlbertoVan Laethem, J. L.Saito, K.Yoshidas, K.Winkler, R.Benedetti, F.Gianni, L.
- [3] AMG 386, a first-in-class, selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumorsEJC SUPPLEMENTS, 2007, 5 (04): : 109 - 110Mita, A.Wang, D.Takimoto, C. H.Martin, D.Nguyen, L.Rasmussen, E.Storgard, C.LoRusso, P.
- [4] Phase I trial in advanced refractory solid tumors of the new drug first-in-class PDM08.JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Barriuso, JorgeMoreno, VictorCoronado, MonicaGalicia, IgnacioSoria, Irenede Castro, JavierBelda-Iniesta, CristobalMartinez Marin, VirginiaCustodio, AnaRedondo, AndresLamarca, AngelaHindi, NadiaLuis Subiza, JoseFrias, JesusFeliu, JaimeCarcas, Antonio
- [5] First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid TumorsJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4142 - +Razak, Albiruni R. AbdulMau-Soerensen, MortenGabrail, Nashat Y.Gerecitano, John F.Shields, Anthony F.Unger, Thaddeus J.Saint-Martin, Jean R.Carlson, RobertLandesman, YosefMcCauley, DilaraRashal, TamiLassen, UlrikKim, RichardStayner, Lee-AnneMirza, Mansoor R.Kauffman, MichaelShacham, SharonMahipal, Amit
- [6] Safety, tolerability, and preliminary efficacy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in combination with pembrolizumab in subjects with solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Jauhari, ShekeabJimeno, AntonioHreno, JenniferBauml, Joshua MichaelGarcia-Ribas, IgnacioOhman, Marie WallenRydberg-Millrud, CamillaCohen, Roger B.
- [7] First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Naing, AungMantia, CharleneMorgensztern, DanielKim, Tae-YongLi, DanengKang, Yoon-KooMarron, Thomas UrbanTripathi, AbhishekGeorge, SabyRini, Brian I.El-Khoueiry, Anthony B.Vaishampayan, Ulka N.Kelley, Robin KateOrnstein, Moshe ChaimAppleman, Leonard JosephHarshman, Lauren C.Lee, BenjaminTannir, Nizar M.Hammers, Hans J.Patnaik, Amita
- [8] ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Ghazaly, Essam AhmedRizzuto, IvanaGabra, HaniHabib, Nagy A.Leonard, Robert C. F.Wasan, HarpreetMcGuigan, ChristopherBlagden, Sarah Patricia
- [9] A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysisJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7Krebs, MatthewBrunsvig, PaalHelland, AslaugVinolas Segarra, NuriaPonce Aix, SantiagoCarcereny Costa, EnricDomine Gomez, ManuelTrigo Perez, Jose ManuelArriola, EdurneGarcia Campelo, RosarioSpicer, JamesThompson, JonathanOrtega Granados, Ana LauraHolt, RobertLorens, JamesShoaib, MuhammadSiddiqui, AbdulSchmidt, EmmettChisamore, MichaelFelip, Enriqueta
- [10] A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in subjects with solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Davar, DiwakarPowderly, John D.Ulahannan, Susanna VarkeyJohnson, Melissa LynneSharma, ManishKrauss, John C.Stagg, RobertFrancica, BrianMoon, AnneJenkins, YonchuPrasit, PeppiDubensky, Thomas WalterWhiting, Sam H.Papadopoulos, Kyriakos P.